Covid-19: UK will not buy Evusheld owing to “insufficient data” on protection, government says

The UK government has said that it will not procure the covid-19 drug Evusheld—a combination of two long acting antibodies, tixagevimab and cilgavimab—because of “insufficient data” on the duration of protection it provides against omicron and its subvariants.The government said that the decision was based on independent clinical advice from Rapid C-19—a multi-agency initiative including NHS England, the Medicines and Healthcare Products Regulatory Agency, the National Institute for Health Research, and the National Institute for Health and Care Excellence (NICE), as well as other health bodies from Scotland, Wales, and Northern Ireland.1Government officials are now set to meet with AstraZeneca again to determine whether any new real world data have emerged from other countries that the expert panel should consider. Additionally, Evusheld will be submitted for a full NICE appraisal, a process that can take around 20 months.In the announcement a government spokesperson said, “Following a robust review of the…
Read Original Article: Covid-19: UK will not buy Evusheld owing to “insufficient data” on protection, government says »